WO2013118960A1 - 효소법을 이용하는 당화혈색소 정량분석용 용혈시약 조성물 - Google Patents
효소법을 이용하는 당화혈색소 정량분석용 용혈시약 조성물 Download PDFInfo
- Publication number
- WO2013118960A1 WO2013118960A1 PCT/KR2012/009715 KR2012009715W WO2013118960A1 WO 2013118960 A1 WO2013118960 A1 WO 2013118960A1 KR 2012009715 W KR2012009715 W KR 2012009715W WO 2013118960 A1 WO2013118960 A1 WO 2013118960A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hemoglobin
- glycated hemoglobin
- reagent composition
- reaction
- quantitative analysis
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/62—Quaternary ammonium compounds
- C07C211/63—Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
- G01N2333/805—Haemoglobins; Myoglobins
Definitions
- Hemolytic reagent composition for quantitative analysis of glycated hemoglobin using enzyme method
- the present invention relates to a hemolytic drug composition for glycated hemoglobin quantitative analysis using the enzyme method.
- the criteria for evaluating the measurement results differ depending on whether the patient has a meal or not, and it is cumbersome to use it, and the measurement value is determined by factors such as the physical condition of the patient at the time of measurement, such as stress, drinking, and fatigue. Changes can occur.
- the measurement of blood glucose using glycated hemoglobin can measure the average blood glucose level of the patient for 3 to 4 months regardless of the diet and the physical condition of the patient, as well as the efficiency of the blood glucose management method performed by the patient. Can be used as an indicator to evaluate. Because the glucose present in the blood reacts with a protein called hemoglobin (hemoglobin) that makes up the blood and over a long period of time, it undergoes amadori rearrangement to produce a modified protein of hemoglobin-glucose called HbAlc. . The glycated hemoglobin is shown below.
- the glycated hemoglobin has a life span of about 90 to 120 days, thereby providing an important data for diagnosing diabetes or determining the level of glycemic control by reflecting the average blood glucose level for three to four months.
- glycated hemoglobin The clinical evaluation of glycated hemoglobin is expressed as a percentage ratio measured relative to the total hemoglobin concentration and within 6.0% represents normal blood glucose levels. Glycated hemoglobin levels are particularly important in the management of diabetic complications. A 1% drop in glycated hemoglobin levels leads to a 14% decrease in myocardial infarction. There are reports of 19% reduction in cataracts, 37% reduction in microvascular disease, 43% reduction in peripheral vascular disease, and 21% reduction in mortality from diabetes.
- routine blood glucose measurement is important for checking the patient's daily health and taking appropriate measures according to the condition, while glycated protein black is necessary to identify the patient's long-term blood glucose control status, to prevent complications, and to take appropriate therapeutic measures. Measurement of glycated hemoglobin is necessary.
- the standard method of measuring glycated hemoglobin which plays an important role in managing blood glucose, is to mix the collected blood sample with a suitable sample, for example, a surfactant such as TX-100, and then hemolyze the layer with boronic acid derivatives. Passed through a thick HPLC column, and then separated from the normal protein, the method of determining the glycated ratio by measuring the specific wavelength of the protein separated by visible light.
- a suitable sample for example, a surfactant such as TX-100
- US Pat. No. 5,541,117 discloses a method of preparing a pad to which an immuno antibody is immobilized, allowing a sample to be developed into a fixed pad, and calculating the intensity of reflected light.
- a method of determining a relative amount of glycated proteins using a marker compound after separating proteins from a sample using a solid phase immobilized with an immuno-antibody has been proposed.
- these methods of electrochemical glycosylated protein crystallization methods are glycated proteins and glycated proteins.
- the enzymatic method is a pretreatment step in which a proteolytic enzyme acts on a glycated protein in a sample and releases a glycated peptide or a glycated amino acid as a substrate for the next step, and a glycated peptide specific enzyme or a glycated amino acid specific enzyme (eg, oxy Multidose) to produce a detectable product (eg, hydrogen peroxide), which leads to the process of measuring the detectable product.
- a proteolytic enzyme acts on a glycated protein in a sample and releases a glycated peptide or a glycated amino acid as a substrate for the next step
- a glycated peptide specific enzyme or a glycated amino acid specific enzyme eg, oxy Multidose
- Japanese Patent Laid-Open No. 5-192193 discloses a ketoamine structure specifically present in fructosamine, and isolates a novel enzyme ketoamineoxidase from various microorganisms which catalyzes the oxidation reaction of this structure.
- the protease pretreated fructosamine was then oxidized in the presence of this enzyme and specifically measured by measuring its product, glucosone or hydrogen peroxide.
- a method for quantifying fructosamine is disclosed.
- Japanese Patent Application Laid-Open No. 2001-95598 discloses that a sample containing glycosylated protein is treated with proteolytic enzymes, freeing glycated peptides, preferably ⁇ -glycosylated peptides, more preferably ⁇ -glycosylated peptides from glycated proteins.
- Measurement of hydrogen peroxide produced by the action of oxidase on the liberated glycosylated peptide, or measurement of the liberated glycosylated peptide using HPLC Method of measuring glycosylated protein in sample and using enzymatic method A reagent kit is disclosed.
- Glycosylated hemoglobin is glucose bound to the valine of the N-terminal ⁇ chain of 1 A ( ⁇ 2 ⁇ 2) of hemoglobin, and the degree of glycation is the ratio of the glycated hemoglobin concentration to the total hemoglobin concentration (3 ⁇ 4>) or The concentration ⁇ ol is expressed.
- the enzyme method to be discussed in the present invention is a fructocyl amino acid through a cleavage enzyme capable of cleaving a protein called protease from the N-terminal ⁇ chain of hemoglobin to which glucose is described above. It should be changed to a monomolecular substance called.
- the generated fructosyl amino acid reacts with the oxidase called FP0X (Fructocyl peptide oxidase) to generate hydrogen peroxide, and the hydrogen peroxide is oxidized through POD (Peroxidase) and the substrate by electrons released through oxidation reaction
- FP0X Fertocyl peptide oxidase
- POD Peroxidase
- the degree of color development through reduction reaction of is analyzed by spectroscopic means to measure glycated hemoglobin.
- the enzymatic method using so many enzymes has the advantage that the accuracy of the result is superior to other methods through the characteristics of the enzyme itself that gives the selectivity, but the reaction conditions are difficult to induce the enzymatic reaction and the reaction time is long and the reaction sensitivity is high. There is a low problem.
- the inventors of the present invention while studying a method for improving the reaction rate and reaction sensitivity in the enzyme method for quantifying glycated hemoglobin, when using a reagent composition containing a zwitterion surfactant and nitrite compound in the hemolytic reagent ionic help not only due to the surface active agent is significantly improved rate of hemolysis, N- terminus of the hemoglobin from hemolyzed ⁇ _ so that the chain can be a number of molecules capable to induce to be exposed to the hemoglobin molecule to participate in the external banung glycated hemoglobin banung Sensitivity and reaction rate are improved, and the nitrite compound allows the hemoglobin protein structure to be flexibly modified, thereby facilitating proteolytic enzymes to cleave the amino acid sequence of ⁇ -terminal ⁇ -chain of hemoglobin, thereby dramatically reducing the overall measurement time. Shortening and improving the accuracy of the measurement results. Out the present invention has been completed. ⁇ Detailed Description of the Invention ⁇
- An object of the present invention is to reduce the measurement time by increasing the reaction speed in the glycated hemoglobin concentration measurement method using the existing enzyme method, and to measure the reaction signal It is to provide a hemolytic reagent composition to maximize the reaction response.
- Another object of the present invention is to provide a method for quantifying glycated hemoglobin using the hemolytic reagent composition.
- the present invention is a zwitterionic surfactant represented by the formula (1);
- hemolytic reagent composition Provided is a hemolytic reagent composition.
- R 1 and R 2 are each independently d-5 linear or branched alkyl; ⁇ is an integer of 1-6; Single bond or Where X is m is an integer of 1-3, R 3 is C 13 linear or branched alkyl,
- the present invention comprises the step of hemolysis of red blood cells with the hemolytic reagent composition (step 1); Measuring the amount of total hemoglobin in which red blood cells are hemolyzed in step 1 (step 2); Selectively cleaving the glycated hemoglobin from which red blood cells are hemolyzed in step 1 to glycoside Vahilis-
- the hemolytic reagent composition comprising the zwitterionic surfactant and the nitrite compound according to the present invention not only significantly improves the hemolysis rate due to the zwitterionic surfactant, but also the hemoglobin N-terminal ⁇ -chain of the hemoglobin released from the hemoglobin molecule.
- the glycated hemoglobin reaction and the reaction rate is improved, and the protein structure of hemoglobin is flexibly modified by the nitrite compound, so that the protease is hemoglobin ⁇ It is easy to cut the terminal ⁇ -chain amino acid sequence, which has an effect of significantly shortening the overall measurement time and improving the accuracy of the measurement results.
- Example 1 is a graph showing that hemolytic reagent compositions according to Examples 1-3 and Comparative Example 3 of the present invention hemolyses erythrocytes over time (the slope change with time in the graph of FIG. It means that it is going on, and the time when the slope change disappears indicates the time when the hemolysis process is finished).
- Figure 2 indicates the potential for hemolysis reagent composition according to Comparative Example 4-8 hours' lapse theta along a graph showing that hemolysis of red blood cells (Figure gradient change with time in the graph of Figure 2 of a red blood cell hemolysis course zero and continue And the time when the change disappears indicates the time of 0 hemolysis process).
- Figure 3 is a graph showing the reaction response to the total hemoglobin of the hemolytic reagent compositions according to Examples 1-3 and Comparative Examples 1-3 of the present invention (the larger the slope in the graph of Figure 3 the greater the sensitivity to the total hemoglobin) ).
- Figure 4 is a graph showing the semi-ungseong sensitivity to the total hemoglobin of the hemolytic reagent compositions according to Comparative Examples 4-5 and Comparative Example 8 (the larger the slope in the graph of Figure 3 shows that the greater the semi-ungseong sensitivity to total hemoglobin).
- FIG. 5 is a graph showing the reaction resistance to glycated hemoglobin of the hemolytic reagent composition according to Examples 1 to 3 and Comparative Example 1 of the present invention (the larger the slope in the graph of FIG. 5, the greater the reaction and response to glycated hemoglobin) ).
- Figure 6 is a graph showing the anti-ungung sensitivity to glycated hemoglobin of the hemolytic reagent composition according to Comparative Examples 2, 4, 5 and 8 (the larger the slope in the graph of Figure 6 shows the semi-ungseong sensitivity and larger for the glycated hemoglobin).
- 7 is a graph showing the banung sensitivity to the glycated hemoglobin in the hemolysis reagent composition according to Example 1 and Comparative Example 10 of the present invention (the larger the slope of the graph of Figure 7 indicates that the banung sensitivity to glycated hemoglobin large) .
- FIG. 8 is a graph showing the anti-ungung sensitivity to glycated hemoglobin of the hemolytic reagent compositions according to Example 1 and Comparative Example 1 of the present invention (in the graph of FIG. 8, the larger the slope, the greater the semi-ungular sensitivity to glycated hemoglobin). [Best form for implementation of the invention]
- glycated hemoglobin glycated hemoglobin
- concentration of total hemoglobin in the blood in particular the measurement sensitivity and measurement of glycated hemoglobin of the total hemoglobin using an improved hemolytic reagent composition to improve the sensitivity and reduce the measurement time.
- both total hemoglobin and glycated hemoglobin levels should be measured.
- the total hemoglobin level was determined by using a characteristic spectroscopic peak in the region around 530 nm of the hemoglobin released from red blood cells during the hemolysis process, which is a pretreatment step for the quantitative analysis of glycated hemoglobin using the enzyme method. Measurement can be made using a spectroscopy device.
- the glycated hemoglobin level can be measured by the enzyme reaction using the proteolytic enzyme, fructosyl peptide oxidase (FP0X), peroxide (POD), and the substrate of the hemolytic blood sample as described above in the background art.
- the present invention is a zwitterionic surfactant represented by the following formula (1);
- a hemolytic reagent composition used in a pretreatment process of glycated hemoglobin quantitative analysis using an enzyme method comprising a nitrite compound.
- R 1 and R 2 are each independently straight or branched alkyl of d- 5 ; n is an integer from 1-6; HX is a single bond or;
- n is 1 and R 3 is straight or branched alkyl of C 13 .
- R 3 is straight or branched alkyl of C 13 .
- R 1 and R 2 are each independently d or 3 straight or branched alkyl
- n is an integer from 1-4;
- % ⁇ X is a single bond or
- X is m is an integer from 1-3, R 3 is straight or branched alkyl of C 13 ,
- M is 1 when X is a single bond, and R 3 is C 13 linear or branched alkyl. Particularly preferably,
- amphoteric surfactants represented by Formula 1 are N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-oethyl
- the bivalent surfactant represented by Chemical Formula 1 serves to increase the hemolysis rate, soften the structure of hemoglobin, and improve the activity of enzyme reactions after the pretreatment process.
- the enzyme reactions after the pretreatment will be described in detail in the method for quantifying glycated hemoglobin using the following enzyme method.
- the zwitterionic surfactant is preferably added at 0.5-1.0 weight 3 ⁇ 4. If the zwitterionic surfactant is less than 0.5 weight 3 ⁇ 4>, there is a problem that the hemolysis reaction reaction rate is lowered or the hemolysis reaction does not occur, and when the amphoteric surfactant exceeds 1.0 weight 3 ⁇ 4, there is a problem that the hemolysis reaction sensitivity is decreased.
- the nitrite compound not only plays a role in facilitating the analysis of total hemoglobin as already known in the prior art, but also softens the structure of the hemoglobin, so that the proteolytic enzyme is used after the pretreatment process It selectively plays a role in obtaining monomolecular fructosyl amino acids by selectively cleaving the sugar I Val-His-
- nitrite compounds such as sodium nitrite, potassium nitrite, magnesium nitrite and calcium nitrite may be used alone or in combination.
- the nitrite compound is preferably added at 1-5 mM. If the nitrite compound is less than 1 mM, there is a problem in that the hemoglobin protein structure cannot be sufficiently flexibly modified. There is a problem in that scattering occurs when measuring the total hemoglobin concentration.
- the present invention comprises the step of hemolysis of red blood cells with the hemolytic reagent composition (step 1);
- step 2 Measuring the amount of total hemoglobin in which red blood cells are hemolyzed in step 1 (step 2);
- step 1 red blood cells are hemolyzed, and the glycosylated hemoglobin is a proteolytic enzyme, which is the glycosylated Va ⁇ His-
- step 4 Reacting with the fructosyl amino acid FPOX ructosyl peptide oxidase) obtained in step 3 to produce hydrogen peroxide (step 4); Reacting the hydrogen peroxide generated in step 4 with POD (peroxidase) to oxidize hydrogen peroxide (step 5);
- step 6 Measuring the amount of coloration induced by oxidation and reduction reaction of the hydrogen peroxide and the substrate oxidized in step 5 (step 6); And
- step 1 is a pretreatment step of hemolysing red blood cells using a hemolytic reagent composition comprising a zwitterionic surfactant represented by Formula 1 according to the present invention and a nitrite compound.
- the zwitterionic surfactant represented by Formula 1 serves to soften the structure of hemoglobin and to improve the activity of enzyme reactions after step 1.
- the zwitterionic surfactant is preferably added at 0.5-1.0 weight 3 ⁇ 4. If the bipolar surfactant is less than 0.5 weight 3 ⁇ 4 » there is a problem that the hemolysis reaction rate is lowered or the hemolysis reaction does not occur, and when it exceeds 1.0 weight%, there is a problem that the hemolysis reaction sensitivity is decreased.
- the nitrite compound not only plays a role in facilitating the analysis of total hemoglobin as already known in the prior art, but also softens the structure of the hemoglobin, pretreatment. After the process, proteolytic enzymes were added to the N-terminal ⁇ -chain of glycated hemoglobin. Va ⁇ His-
- nitrite compounds such as sodium nitrite, potassium nitrite, magnesium nitrite and calcium nitrite may be used alone or in combination.
- the nitrite compound is preferably added at 1-5 mM. If the nitrite compound is less than 1 mM, there is a problem in that hemoglobin protein structure is not sufficiently flexibly modified, and if the nitrite compound is more than 5 mM, scattering occurs when measuring total hemoglobin concentration.
- step 2 is a step in which red blood cells are hemolyzed in step 1 to determine the amount of better total hemoglobin. Specifically, the total hemoglobin level was measured using a spectroscopy device such as UV / Vis using the fact that the hemoglobin released from red blood cells in the hemolysis process of step 1 was characterized by a characteristic spectroscopic peak in the region around 530 nm. can do .
- the step 3 is that the red blood cells are hemolyzed in step 1 to selectively cleave the glycosylated hemoglobin of the glycosylated hemoglobin in the N-terminal ⁇ -chain of the glycosylated hemoglobin. To obtain a monomolecular fructosyl amino acid.
- protease Bacillus, Aspergillus, Streptomyces genus, protease derived from the genetic recombination of these microorganisms can be used alone or in combination.
- the protease is preferably added at 500-1000 U / mL. If the protease is less than 500 u / mL, the sensitivity of the reaction is reduced. If exceeded, the enzymes used together are also decomposed together to reduce reaction there is a problem.
- step 4 is a step of reacting the fructosyl amino acid obtained in step 3 with fructosyl peptide oxidase (FPOX) to generate hydrogen peroxide (0 2 ).
- FPOX fructosyl peptide oxidase
- step 5 is a step of oxidizing hydrogen peroxide by reacting hydrogen peroxide generated in step 4 with POD (peroxidase).
- the P0D is preferably added at 5-20 U / mL. If the P0D is less than 5 U / mL, there is a problem that the sensitivity of the overall reaction decreases. If the P0D exceeds 20 U / mL, the color of the enzyme itself is similar to that of the hemoglobin, so that the concentration of glycated hemoglobin is measured. There is a problem that interferes with it.
- step 6 is a step of measuring the amount of color induced by the hydrogen peroxide and the substrate oxidized in the step 5 to cause the oxidation and reduction reaction.
- the substrate serves to cause color reaction through oxidized hydrogen peroxide and oxidation / reduction reaction produced by the P0D, and dyes such as DA-67 and DA-64 may be used.
- the substrate is preferably added less than 0.12 niM. if,. If the substrate exceeds 0.12 mM, there is a problem that spontaneous color change occurs, causing errors in spectroscopic measurements. Since the substrate is an unstable substance that spontaneously discolors by the outside and the temperature, special care is required for its use.
- step 7 is a step of quantifying glycated hemoglobin concentration in blood samples by comparing the amount of total hemoglobin measured in step 2 with the amount of glycated hemoglobin measured in step 6 relatively. .
- the amount of glycated hemoglobin relative to the total hemoglobin amount can be calculated and expressed as a percentage.
- the amount of total hemoglobin and glycated hemoglobin measurement quantity measured in the step 6 of the i stage 2 can be measured with a spectroscopic device, such as a UV / Vis.
- the hemolytic reagent composition comprising the zwitterionic surfactant and the nitrite compound according to the present invention not only significantly improves the hemolysis rate due to the zwitterionic surfactant, but also the N-terminal ⁇ of the hemoglobin released from hemolysis. -Induce the chain to be exposed to the outside of the hemoglobin molecule, so that as many molecules as possible to participate in the reaction to improve the glycosylated hemoglobin reaction and reaction speed, and the nitrite compound is flexibly modified protein structure of hemoglobin Enzyme cleaves amino acid sequence that is the ⁇ -terminal ⁇ -chain of hemoglobin It is easy to make it possible to significantly shorten the overall measurement time and improve the accuracy of the measurement results.
- a 100 iiiM MES buffer 800 U / mL of microbial protease with protease, 1 U / mL of fructosyl peptide oxidase (FPOX), 10 U / mL of POD (peroxidase) and 0.12 mM DA-67 (dye) as substrate
- FPOX fructosyl peptide oxidase
- POD peroxidase
- dye 0.12 mM DA-67
- Hemolytic reagent composition by mixing together 3— (dimethyl (3-tetradecaneamidopropyl) ammonio) propane-1-sulfonate 0.75 mg / niL with 2 mM NaN0 2 as a nitrite compound in 100 mM MES buffer 1 was prepared.
- Hemolysis was carried out in the same manner as in Example 1, except that 0.75 mg / mL of 4- (dimethyl (3-tetradecaneamidopropyl) ammonio) butane-1-sulfonate was used instead of the surfactant used in Example 1.
- Reagent composition 2 was prepared.
- Hemolytic reagent composition 3 was prepared in the same manner as in Example 1 except for using (dimethyl (tetradecyl) ammonio) propane 1-sulfonate 0.75 rag / mL.
- Hemolytic reagent composition 4 was prepared in the same manner as in Example 1, except that purified water was used instead of the surfactant used in Example 1. Comparative Example 2 Preparation of Hemolytic Reagent Compositions Used in the Pretreatment Process of Quantitative Analysis of Glycated Hemoglobin 5
- Hemolytic reagent composition 5 was prepared in the same manner as in Example 1 except for using 0.75 mg / mL of 6- (hydroxymethyl) ⁇ tetrahydro-2H-pyranjan 3, 4 and 5-tree.
- Hemolytic reagent composition 6 was prepared in the same manner as in Example 1 except that (dodecyldimethylammonio) butanoate 0.75 mg / mL was used. '
- the hemolysis reagent composition 7 was prepared in the same manner as 1.
- Hemolysis was carried out in the same manner as in Example 1, except that 0.75 mg / mL of 3- (dimethyl (3-palmitamidopropyl) ammono) propane-1-sulfonate was used instead of the surfactant used in Example 1.
- Reagent composition 8 was prepared.
- a hemolytic reagent composition 9 was prepared in the same manner as in Example 1 except that 0.75 mg / mL of 3- (dimethyl (octyl) ammonio) propane-1 -sulfonate was used instead of the surfactant used in Example 1. .
- Hemolytic reagent composition 10 was prepared in the same manner as in Example 1, except that 0.75 mg / mL of 3 ′ (decyldimethylammonio) propane-1-sulfonate was used instead of the surfactant used in Example 1. Comparative Example 8 Preparation of Hemolytic Reagent Composition for Use in Pretreatment of Glycated Hemoglobin Quantitative Analysis 11
- a hemolytic reagent composition 11 was prepared in the same manner as in Example 1 except for using (dodecyldimethylammonio) propane-1-sulfonate 0.75 mg / mL.
- a hemolytic reagent composition 12 was prepared in the same manner as in Example 1 except that 0.75 mg / mL of (nuxadecyldimethylammonio) propane-1-sulfonate was used. Comparative Example 10 Preparation of Hemolytic Reagent Composition for Use in Pretreatment of Glycated Hemoglobin Quantitative Analysis 13
- Hemolytic reagent composition 13 was prepared in the same manner as in Example 1 except that 2 mM NaN0 2 was not used as the nitrite compound. Chemical structures of the bivalent surfactants used in Examples 1-3 and Comparative Examples 1-9 are shown in Table 1 below.
- solubility of the sample itself In order to use the surfactant, the solubility of the sample itself must be excellent. Thus, since it is not possible to firstly dissolve the user body, solubility of the surfactant was evaluated as a precondition for use. Specifically, the surfactants used in Examples 1 to 3 and Comparative Examples 1-9 were dissolved in distilled water so as to have a concentration of 0.75 mg / ml, and the dissolution was determined, and the results are shown in Table 2 below.
- the hemolytic reagent compositions prepared in Examples 1-3 and Comparative Examples 1-8 were reacted with blood for 1: 400 (blood: hemolytic reagent) for 5 minutes. Absorbance change (at 530 nm) between 0 and 5 minutes was measured using a UV / Vis device (Model: UV-1800, manufacturer: Shimadzu), and the results are shown in FIGS. 1, 2 and Table 3 below. .
- Example 1 is a graph showing that the hemolytic reagent composition according to Examples 1-3 and Comparative Example 1 3 of the present invention hemolyses erythrocytes over time (the slope change with time in the graph of FIG. 1 is a hemolytic process of erythrocytes). This means that the process continues, and the time when the change of the slope disappears indicates the time when the hemolysis process is completed).
- Figure 2 is a graph showing that the hemolytic reagent composition according to Comparative Example 4-8 hemolyzed red blood cells over time (in the graph of Figure 2, the change in the slope with time means that the hemolysis process of red blood cells is continuing o For example, the time at which the change in slope disappears represents the time at which the hemolysis process is completed.
- the hemolytic reagent composition prepared in Example 1-3 shows a fast hemolysis rate within about 1 minute and the change in the slope over time ⁇ hemolysis of the hemocytosis In terms of meaning that it is still true, it can be seen that it shows an intraocular signal with little change in inclination.
- Example 3 shows a fast hemolysis rate within about 1 minute and the change in the slope over time ⁇ hemolysis of the hemocytosis In terms of meaning that it is still true, it can be seen that it shows an intraocular signal with little change in inclination.
- the hemolytic reagent composition shows the fastest rate of hemolysis .
- Figure 3 is a graph showing the anti-ungung sensitivity to total hemoglobin of the hemolytic reagent composition according to Examples 1-3 and Comparative Examples 1-3 of the present invention (in the graph of FIG. Big one).
- FIG. 4 is a graph showing the anti-ungung sensitivity to total hemoglobin of the hemolytic reagent compositions according to Comparative Examples 4-5 and 8 (the larger the swelling in the graph of FIG. 3, the greater the reaction response to the total hemoglobin).
- the substrate must be colored through the reaction of hydrogen peroxide and peroxidase produced through enzyme reactions, so that accurate quantitative analysis is possible.
- the substrate may be colored through the reaction between the substrate and the surfactant, resulting in errors in the quantitative analysis.
- the reaction between the surfactant and the substrate was tested as follows.
- the hemolysis reagents prepared in Examples 1-3 and Comparative Examples 1, 2, 4, 5, and 8 were not reacted with blood samples, and the absorbance was analyzed by the UV / Vis apparatus used in Example 2.
- the surfactants included in the hemolytic reagents prepared in Examples 1 to 3 and Comparative Examples 1, 2, 4, 5, and 8 did not react with the substrate, and thus were found to be suitable for quantitative analysis.
- the response and the reaction rate for the glycated hemoglobin should be excellent.
- the effect of the hemolytic reagent composition according to the present invention on the glycated hemoglobin reaction and the reaction rate was as follows. Specifically, in the case of response sensitivity, four blood samples having different glycated hemoglobin concentrations (72 ⁇ M, 120 ⁇ , 152 ⁇ , 264 ⁇ ) were prepared.
- the absorbance at 633 nm which is a wavelength region where DA-67 (manufacturer: Wako) used as a substrate, was specifically measured in the enzyme reaction composition prepared in Preparation Example 1, was the same as that used in Experimental Example 2. It was measured using the / Vis device, the results are shown in Figures 5-6. In addition, the slope of the graph showing the glycated hemoglobin reaction sensitivity in Figure 5 ⁇ 6 is shown in Table 5 below.
- Figure 5 is a graph showing the reaction response to glycated hemoglobin of the hemolytic reagent composition according to Example 1 ⁇ 3 and Comparative Example 1 of the present invention (the larger the slope in the graph of Figure 5 the reaction sensitivity and the reaction rate for glycated hemoglobin) Big one).
- Figure 6 is a graph showing the reaction resistance to glycated hemoglobin of the hemolytic reagent composition according to Comparative Examples 2, 4, 5 and 8 (the larger the slope in the graph of Figure 6 shows that the reaction sensitivity and reaction rate for glycated hemoglobin is larger) ).
- the following experiment was conducted to determine the reaction rate for glycated hemoglobin.
- reaction rate was compared with the reaction sensitivity per unit time.
- reaction time was fixed to 3 minutes
- the reaction rate was compared by the slope of each hemolysis reagent. 5 and 6 can be seen as a reaction rate, because the reaction rate is slow even if the reaction rate of any one of the two reactions of hemolysis and enzyme reaction reaction rate is slow because the reaction reaction slope is small.
- Example 1-3 the slope of the calibration curve was found to show a large value of about 0.09-0.1.
- the length of the tail chain was all carbon The molecular structure common to 14 was confirmed. This suggests that surfactants consisting of 14 carbons in the tail chain help glycated hemoglobin and enzymes easily react.
- nitrite compounds are known to be used to measure total hemoglobin.
- the protein structure of hemolysed hemoglobin is flexibly changed to provide a supporting property for proteolytic enzymes to facilitate the cleavage of the sequence.
- Example 1 three blood samples (52 uM, 98 uM, 125 ⁇ ) having different glycated hemoglobin concentrations were prepared, and each of the blood samples was prepared in Example 1 and Comparative Example 10 (the nitrite compound in the composition of Example 1). After reacting for 1 minute at a ratio of 1: 400 (blood: hemolytic reagent) and the hemolytic reagent composition prepared in the above), the mixture was added to the enzyme reaction composition prepared in Preparation Example 1 by the following process and reacted for 3 minutes to glycated hemoglobin. Was measured.
- the absorbance at 633 nm which is a wavelength region where DA-67 (manufacturer: Wako) used as a substrate, was specifically measured in the enzyme reaction composition prepared in Preparation Example 1, was the same as that used in Experimental Example 2. It was measured using the / Vis device, the results are shown in FIG.
- Figure 7 is a graph showing the anti-ungung sensitivity to glycated hemoglobin of the hemolytic reagent composition according to Example 1 and Comparative Example 10 of the present invention (the larger the slope in the graph of Figure 7 shows that the semi-ungseong sensitivity to glycated hemoglobin).
- the reaction rate (slope of the black curve) for glycated hemoglobin was 0.10386, whereas' the hemolytic reagent prepared in Comparative Example 10 was used.
- the reaction rate for glycated hemoglobin was 0.02169, which was about 5 times larger.
- Example 1 In order to find out whether the surfactant used in the present invention induces the hemoglobin ⁇ —terminal-chain to be exposed outside the hemoglobin molecule so that as many molecules as possible can participate in reaction and affect the glycated hemoglobin reaction sensitivity.
- the experiment was as follows. Specifically, four blood samples having different glycated hemoglobin concentrations (72 ⁇ M, 120 ⁇ , 152 ⁇ , and 264 ⁇ ) were prepared, and each of the blood samples was prepared in Example 1 and Comparative Example 1 (Example 1).
- the absorbance at 633 nm which is the wavelength region where DA-67 (manufacturer: Wako) specifically used as a substrate in the enzyme reaction composition prepared in Preparation Example 1, was the same as that used in Experiment 2 Measurement was made using a UV / Vis device, and the results are shown in FIG. 8.
- FIG. 8 is a graph showing the anti-ungung sensitivity to glycated hemoglobin of the hemolytic reagent compositions according to Example 1 and Comparative Example 1 of the present invention (in the graph of FIG. 8, the larger the slope, the greater the semi-ungular sensitivity to glycated hemoglobin).
- the hemolytic reagent composition comprising the bivalent surfactant and the nitrite compound according to the present invention not only significantly improves the hemolysis rate due to the zwitterionic surfactant, but also the ⁇ -terminus of hemolytic hemoglobin.
- ⁇ -chain can be exposed to outside the hemoglobin molecule, so that as many molecules as possible can participate in the reaction, the glycosylated hemoglobin response sensitivity and reaction rate are improved, and the nitrite compound flexibly modifies the hemoglobin protein structure.
- the protease facilitates the cleavage of the amino acid sequence of the ⁇ -terminal ⁇ - body of hemoglobin, thereby dramatically reducing the overall measurement time and improving the accuracy of the measurement results.
- As a hemolytic reagent composition for glycated hemoglobin quantitative analysis Can be useful.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201280069408.3A CN104105968B (zh) | 2012-02-10 | 2012-11-16 | 用于使用酶法对糖化血红蛋白进行定量分析的溶血试剂组合物 |
JP2014556464A JP5829766B2 (ja) | 2012-02-10 | 2012-11-16 | 酵素法を利用したヘモグロビンA1c定量分析のための溶血試薬組成物 |
US14/373,977 US9435792B2 (en) | 2012-02-10 | 2012-11-16 | Hemolysis reagent composition for hemoglobin A1C quantitative analysis using enzymatic method |
EP12867965.1A EP2813854B1 (en) | 2012-02-10 | 2012-11-16 | Hemolysis reagent composition for hemoglobin a1c quantitative analysis using enzymatic method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0013841 | 2012-02-10 | ||
KR1020120013841A KR101207418B1 (ko) | 2012-02-10 | 2012-02-10 | 효소법을 이용하는 당화혈색소 정량분석용 용혈시약 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013118960A1 true WO2013118960A1 (ko) | 2013-08-15 |
Family
ID=47906733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/009715 WO2013118960A1 (ko) | 2012-02-10 | 2012-11-16 | 효소법을 이용하는 당화혈색소 정량분석용 용혈시약 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9435792B2 (ko) |
EP (1) | EP2813854B1 (ko) |
JP (1) | JP5829766B2 (ko) |
KR (1) | KR101207418B1 (ko) |
CN (1) | CN104105968B (ko) |
WO (1) | WO2013118960A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015169862A1 (de) * | 2014-05-06 | 2015-11-12 | Diasys Diagnostic Systems Gmbh | Enzymatische bestimmung von hba1c |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101723025B1 (ko) * | 2016-10-12 | 2017-04-07 | 주식회사 아이센스 | 장기 안정성이 향상된 시료를 포함하는 당화혈색소 정량분석용 키트 |
KR101974515B1 (ko) * | 2017-02-14 | 2019-05-07 | 주식회사 아이센스 | 당화혈색소 정량분석용 키트 |
MX2019010478A (es) | 2017-03-03 | 2019-12-19 | Polymer Technology Systems Inc | Sistemas y métodos para la detección y cuantificación enzimáticas de a1c. |
US11703513B2 (en) | 2017-08-07 | 2023-07-18 | Polymer Technology Systems, Inc. | Systems and methods for enzymatic A1C detection and quantification |
CN109680036A (zh) * | 2017-10-02 | 2019-04-26 | 爱科来株式会社 | 糖化蛋白质的测定 |
CN109682796A (zh) * | 2017-10-02 | 2019-04-26 | 爱科来株式会社 | 糖化蛋白质的测定 |
JP7226955B2 (ja) * | 2017-10-02 | 2023-02-21 | アークレイ株式会社 | 糖化蛋白質の測定 |
CN110506122B (zh) * | 2017-12-12 | 2023-09-29 | 聚合物技术***公司 | 用于酶促a1c检测和定量的样品制备***和方法 |
CN108562751A (zh) * | 2018-05-04 | 2018-09-21 | 深圳市西尔曼科技有限公司 | 酶膜及其制备方法、糖化血红蛋白的检测方法 |
EP3841384A4 (en) * | 2018-08-22 | 2022-05-11 | Quest Diagnostics Investments LLC | MICROSAMPLING DETECTION IN DIABETES |
CN112334767B (zh) * | 2018-09-12 | 2024-01-09 | 积水医疗株式会社 | 血红蛋白类测定用试剂以及血红蛋白类的测定方法 |
CN113196064B (zh) * | 2019-01-29 | 2022-09-27 | 美国西门子医学诊断股份有限公司 | 降低血红蛋白A1c测定中的英脱利匹特/脂血干扰的浊度归一化算法和方法 |
KR20220082858A (ko) * | 2019-10-17 | 2022-06-17 | 노바 바이오메디컬 코포레이션 | 응고 검정 장치 및 이의 방법 |
CN112280765B (zh) * | 2020-09-27 | 2021-10-08 | 扬州大学 | 磺基甜菜碱表面活性剂在提高菠萝蛋白酶活性中的应用 |
CN113588750B (zh) * | 2021-07-16 | 2024-01-19 | 成都云芯医联科技有限公司 | 一种同时测量血红蛋白与糖化血红蛋白的电化学测试卡及其制作方法 |
CN118176419A (zh) * | 2021-12-13 | 2024-06-11 | 泰尔茂株式会社 | 生物体成分浓度测定试剂、测定方法和传感器 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05192193A (ja) | 1991-07-29 | 1993-08-03 | Genzyme Ltd | 非酵素的グリコシル化タンパク質の検定法 |
US5541117A (en) | 1992-03-05 | 1996-07-30 | Boehringer Mannheim Gmbh | Immunological method for the determination of a haemoglobin derivative |
JPH10319021A (ja) * | 1997-05-13 | 1998-12-04 | Bayer Corp | シアン化物含有ヘモグロビン試薬組成物及び自動血液分析器で許容可能な精度及び正確さを提供し且つ白血球による妨害がない方法 |
JP2001095598A (ja) | 1999-10-01 | 2001-04-10 | Kikkoman Corp | 糖化蛋白質の測定方法 |
WO2002021142A1 (fr) * | 2000-09-07 | 2002-03-14 | Wako Pure Chemical Industries, Ltd. | Procede de quantification de l'hemoglobine totale et de la glycohemoglobine |
US20030044995A1 (en) * | 2001-04-04 | 2003-03-06 | Sigma-Aldrich Co. | Cyanide-free reagent, and method for detecting hemoglobin |
JP2007147630A (ja) * | 2002-06-14 | 2007-06-14 | Arkray Inc | スルホン酸化合物およびニトロ化合物を用いた測定方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100394187C (zh) * | 2002-06-14 | 2008-06-11 | 爱科来株式会社 | 使用磺酸化合物和硝基化合物的测定方法 |
JP3910156B2 (ja) * | 2003-05-28 | 2007-04-25 | アークレイ株式会社 | 試料の安定化方法 |
US7150995B2 (en) * | 2004-01-16 | 2006-12-19 | Metrika, Inc. | Methods and systems for point of care bodily fluid analysis |
WO2010041715A1 (ja) * | 2008-10-09 | 2010-04-15 | 協和メデックス株式会社 | 新規フルクトシルペプチドオキシダーゼ |
FR2947632B1 (fr) * | 2009-07-01 | 2011-11-11 | Sebia Sa | Analyse et dosage d'hemoglobines glyquees par electrophorese capillaire, compositions tampon et kits pour electrophorese capillaire |
-
2012
- 2012-02-10 KR KR1020120013841A patent/KR101207418B1/ko active IP Right Grant
- 2012-11-16 CN CN201280069408.3A patent/CN104105968B/zh active Active
- 2012-11-16 WO PCT/KR2012/009715 patent/WO2013118960A1/ko active Application Filing
- 2012-11-16 EP EP12867965.1A patent/EP2813854B1/en active Active
- 2012-11-16 US US14/373,977 patent/US9435792B2/en active Active
- 2012-11-16 JP JP2014556464A patent/JP5829766B2/ja active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05192193A (ja) | 1991-07-29 | 1993-08-03 | Genzyme Ltd | 非酵素的グリコシル化タンパク質の検定法 |
US5541117A (en) | 1992-03-05 | 1996-07-30 | Boehringer Mannheim Gmbh | Immunological method for the determination of a haemoglobin derivative |
JPH10319021A (ja) * | 1997-05-13 | 1998-12-04 | Bayer Corp | シアン化物含有ヘモグロビン試薬組成物及び自動血液分析器で許容可能な精度及び正確さを提供し且つ白血球による妨害がない方法 |
JP2001095598A (ja) | 1999-10-01 | 2001-04-10 | Kikkoman Corp | 糖化蛋白質の測定方法 |
WO2002021142A1 (fr) * | 2000-09-07 | 2002-03-14 | Wako Pure Chemical Industries, Ltd. | Procede de quantification de l'hemoglobine totale et de la glycohemoglobine |
US20030044995A1 (en) * | 2001-04-04 | 2003-03-06 | Sigma-Aldrich Co. | Cyanide-free reagent, and method for detecting hemoglobin |
JP2007147630A (ja) * | 2002-06-14 | 2007-06-14 | Arkray Inc | スルホン酸化合物およびニトロ化合物を用いた測定方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2813854A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015169862A1 (de) * | 2014-05-06 | 2015-11-12 | Diasys Diagnostic Systems Gmbh | Enzymatische bestimmung von hba1c |
WO2015169511A3 (de) * | 2014-05-06 | 2015-12-30 | Diasys Diagnostic Systems Gmbh | Enzymatische bestimmung von hba1c |
CN106461682A (zh) * | 2014-05-06 | 2017-02-22 | 德赛诊断***有限公司 | HbA1c的酶促测定 |
CN106461682B (zh) * | 2014-05-06 | 2018-09-21 | 德赛诊断***有限公司 | HbA1c的酶促测定 |
US10093959B2 (en) | 2014-05-06 | 2018-10-09 | Diasys Diagnostic Systems Gmbh | Enzymatic determination of HBA1c |
US10202632B2 (en) | 2014-05-06 | 2019-02-12 | Diasys Diagnostic Systems Gmbh | Enzymatic determination of HbA1c |
Also Published As
Publication number | Publication date |
---|---|
JP5829766B2 (ja) | 2015-12-09 |
CN104105968A (zh) | 2014-10-15 |
EP2813854B1 (en) | 2016-09-07 |
KR101207418B1 (ko) | 2012-12-04 |
US9435792B2 (en) | 2016-09-06 |
US20140370539A1 (en) | 2014-12-18 |
EP2813854A4 (en) | 2014-12-17 |
JP2015509361A (ja) | 2015-03-30 |
CN104105968B (zh) | 2016-03-23 |
EP2813854A1 (en) | 2014-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013118960A1 (ko) | 효소법을 이용하는 당화혈색소 정량분석용 용혈시약 조성물 | |
JP3971702B2 (ja) | 糖化ヘモグロビンの選択的測定方法 | |
JP6810874B2 (ja) | 糖化ヘモグロビンの測定方法 | |
Hatada et al. | Development of a screen-printed carbon electrode based disposable enzyme sensor strip for the measurement of glycated albumin | |
CN107870170B (zh) | 一种酶化学发光法测定糖化血清白蛋白的试剂盒 | |
JP2011224025A (ja) | 糖化タンパク質の測定のための方法および組成物 | |
JP4861986B2 (ja) | タンパク質の切断方法およびその用途 | |
JPWO2003064683A1 (ja) | 酸化還元反応を用いた糖化タンパク質の測定方法および測定キット | |
Vigneshwaran et al. | Autofluorescence characterization of advanced glycation end products of hemoglobin | |
JP5261180B2 (ja) | 食後高血糖マーカー、その測定方法およびその用途 | |
Yagi et al. | Glycative stress and anti-aging: 2. The Evaluation of Glycative Stress: Measurement of blood glucose, glycated proteins and intermediates | |
Katchunga et al. | Glycated nail proteins as a new biomarker in management of the South Kivu Congolese diabetics | |
JP7020484B2 (ja) | 糖化ヘモグロビンの測定方法 | |
WO2021192466A1 (ja) | ヘモグロビンの影響軽減方法、糖化ヘモグロビンの測定方法、糖化ヘモグロビン測定試薬、及び糖化ヘモグロビン測定キット | |
US8187831B2 (en) | Determination of ions using ion-sensitive enzymes | |
JP2001258593A (ja) | 糖化アルブミンの測定方法 | |
JP2007181466A (ja) | 糖化ヘモグロビンの選択的測定方法 | |
JP2006266811A (ja) | グリコヘモグロビン量及び総ヘモグロビン量の分析方法 | |
Ramanathan et al. | Usefulness of Estimation of Glycated Albumin and Glycosylated Haemoglobin in Indian Diabetic Chronic Kidney Disease Patients | |
Ramanathan et al. | Usefulness of Estimation of Glycated Albumin and Glycosylated Haemoglobin in Indian Diabetic Chronic Kidney Disease Patients. OA Maced J Med Sci. 2014 Sep 15; 2 (3): 444-447 | |
Shaligram et al. | Standard of Care in Diagnosis of Diabetes Mellitus: HbA1c | |
JPH11264824A (ja) | ヒトヘモグロビンの検出方法、ヒトヘモグロビン検出用物質の製造方法、ヒトヘモグロビン検出装置、トイレ装置 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201280069408.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12867965 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14373977 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2012867965 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012867965 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014556464 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |